INTRODUCTION

Type-1 diabetes mellitus (T1DM), is a complex chronic condition\(^1\)\(^,\)\(^2\) that results from autoimmune-mediated beta cell destruction and leads to an absolute insulin deficiency.\(^3\) Insulin is the core treatment of T1DM. Achieving stable blood glucose levels and adequate hemoglobin A1c (HbA1c) and preventing the development of micro vascular and macro vascular complications are the main goals of treatment in T1DM.\(^4\)\(^,\)\(^5\) The Diabetes Control and Complications Trial (DCCT) has shown that intensive insulin regimens to reduce glucose to near-normal levels are associated with delays in incidence and progression of diabetes-related complications.\(^6\)\(^,\)\(^7\)

Although beneficial, insulin therapy has some shortcomings. Insulin resistance may develop in some patients. Intensive insulin therapy is also
associated with increased risk of hypoglycemia, and weight gain. Thus the goals of good glycemic control are often not achievable. Physiologic changes in insulin sensitivity during growth and pubertal development also results in insulin resistance in both adult and youth with T1DM. In addition to glycemic control, patients with T1DM do not meet the targets of metabolic control for BMI, blood pressure, low-density lipoprotein (LDL)-cholesterol, and triglycerides.

All the aforementioned data have stimulated interest in studying other potential therapies for T1DM including noninsulin pharmacological therapies. Since Type-2 diabetes mellitus (T2DM) is mainly the result of insulin resistance, currently approved medications for the treatment of Type-2 diabetes focus on reducing insulin resistance and preventing weight gain by different mechanisms of action. Acarbose (Alpha-Glucosidase Inhibitor) and metformin are of T2DM medications. Acarbose inhibits digestion into monosaccharides and offsetting post-prandial glucose rise while metformin inhibits hepatic glucose production and improves peripheral insulin sensitivity. The effectiveness of acarbose and metformin in patients with T1DM has been evaluated in previous studies separately but studies that focus on comparing the effect of these two drugs are limited. The aim of this study was to compare adjunctive therapy with metformin and acarbose in patients with Type-1 diabetes mellitus.

METHODS

The current study compared the results of two placebo-controlled clinical trials conducted in two different time periods on 40 patients with Type-1 diabetes. Both clinical trials were approved by the Ethics Committee of Institute of Endocrinology and Metabolism, Iran University of Medical Sciences (IRCT201102165844N1). Patients participating in these clinical trials were selected from the ones who referred to the endocrinologist’s office and enrolled after signing the written informed consent. The inclusion criteria were: age 15-25 years, puberty stage of 2-5 Tanner, at least three years history of diabetes, HbA1C7-11 (within the recent six months). The exclusion criteria were: diabetic nephropathy (albumin excretion over 300 mg/dL), proliferative retinopathy, liver or renal failure and any severe illness, eating disorders and a history of recurrent diabetic ketoacidosis (more than two times within the last year leading to reduction of the level of consciousness and hospitalization). The patient groups went through two treatment interventions.

In the first study, metformin was added to the therapeutic regimen of the subjects and results were compared with that of the placebo group. The initial dose of metformin was 500 mg/day and gradually increased from the first week, in a way that the maximum doses in the subjects under 50 kg, 50-70 kg and over 75 kg were increased to 1000, 1500 and 2000 mg, respectively. Subjects were advised to take the medicine with food to reduce digestive complications. The study period was three months and subjects were examined every month and monitored by telephone every week.

Six month after the first study and during the second study, acarbose was added to the therapeutic regimen of the subjects and the results were compared to those of the placebo group. Subjects received acarbose 25 mg three times a day for two weeks and then 50 mg three times a day for 10 weeks. The regimen was administered as tablets before each meal. The subjects were advised to monitor their blood sugar by glucometer and use glucose powder whenever symptoms of hypoglycemia i.e. lethargy, sweating and heart palpitations develop; if their blood glucose was less than 50 mg/dL, they were advised to refer to the hospital. Subjects were examined every month and monitored by telephone every week. In both studies, subjects were advised to check their fasting blood sugar (FBS), two-hour postprandial plasma glucose (2hpp) after each meal and add a unit of NPH insulin (Neutral Protamine Hagedorn) every night for each extra 50 mg/dL of FBS higher than 150 mg/dL; and add two units of regular insulin to the same turn for each 2hpp higher than 200 mg/dL. In addition, they were advised to record the frequencies and the time of hypoglycemia and the interval from the previous meal. They were also advised to refer to the hospital in case of symptomatic hypoglycemia and to stay in touch with the plan executor to match all insulin doses. The adverse effects caused by oral medication (bloating, stomachache, diarrhea and hypoglycemia) were recorded.

The body weight of the subjects were monitored monthly using a digital scale with accuracy of 0.1 kg, the height was measured by the tape meter while their heels and shoulders were attached to the wall; the blood pressure was measured using a Richter mercury sphygmomanometer with appropriate brachial cuff. The measurements were conducted by the same person. Body mass index (BMI) was measured based on the equation: weight (in kg) divided by the square of height (in meter). Also, the mean of insulin dose was measured.
based on insulin dosage and the mean of FBS and 2hpp during the last seven days before monthly examination.

The blood glucose was measured in home by the subjects using Accuchek glucometer device. Finally, HbA1C was measured using Jame-eh kit through column chromatography; the levels of triglyceride, cholesterol, high density and low density lipoproteins (HDL and LDL) were measured using Pars kit (Iran) by GHOD-PAP and Hyper-G; the level of LDL was measured using Pars Azmoon kit (Iran) by enzymatic method in the beginning and at the end of the study.

Data were presented as mean ± SD. The mean of evaluated variables were compared before and after the treatment, using paired T-test. The difference between the mean of variables before and after the treatment were calculated and compared with the results of the paired T-test for the two types of treatment.

RESULTS

Mean age was 19.31±1.25 in the beginning of the first study. Of 20 patients, 10 were male. None of the patients were excluded or missed to follow up in both studies. The comparison of laboratory characteristics and insulin intake before and after adjunctive therapy with metformin and acarbose has been shown in Table-I. After treatment with metformin, mean FBS and TG was significantly decreased; but only mean two hour post prandial and regular insulin intake were significantly decreased after treatment with acarbose.

Comparison of mean difference after intervention between two groups has been shown in Table-II. The mean decrease in FBS and HbA1C after treatment with metformin was significantly higher than treatment with acarbose. The mean decrease in 2hpp, TGs, Cholesterol, LDL, and regular insulin intake after treatment with acarbose was significantly higher than treatment with metformin.

DISCUSSION

In order to provides an efficacious and safe alternative for glycemic improvement in Type-1 patients mellitus, our test group received metformin firstly and then acarbose during the trial. It has been shown that acarbose/metformin is well-tolerated in T1DM patients. Based on our result, a significant decrease in FBS and TG levels was observed in the metformin group during follow-up but acarbose

Table-I: Comparison of laboratory characteristics and insulin intake before and after adjunctive therapy with metformin and acarbose in T1DM patients.

|                     | Before             | After              | P-value |
|---------------------|--------------------|--------------------|---------|
| **Metformin**       |                    |                    |         |
| BMI                 | 23.21±1.40         | 22.80±1.80         | 0.410   |
| FBS                 | 168.80±19.90       | 113.56±14.90       | <0.001  |
| 2 h pp              | 198.70±18.5        | 182.70±16.30       | 0.006   |
| HbA1C               | 8.36±0.80          | 8.02±0.63          | 0.143   |
| TGs                 | 96.90±14.0         | 87.94±13.45        | 0.045   |
| Cholesterol         | 135.75±24.10       | 131.81±22.65       | 0.597   |
| HDL-C               | 35.12±9.80         | 36.28±9.60         | 0.707   |
| LDL-C               | 81.00±12.66        | 79.25±13.90        | 0.679   |
| Insulin (NPH)       | 33.40±8.20         | 31.60±8.10         | 0.489   |
| Insulin (Regular)   | 18.5±7.60          | 17.60±6.80         | 0.695   |
| **Acarbose**        |                    |                    |         |
| BMI                 | 23.96±1.70         | 23.70±1.40         | 0.600   |
| FBS                 | 130.30±18.90       | 120.10±18.70       | 0.094   |
| 2 h pp              | 180.20±22.70       | 154.80±18.70       | <0.001  |
| HbA1C               | 7.80±0.45          | 7.60±0.40          | 0.145   |
| TGs                 | 166.40±33.60       | 148.80±30.95       | 0.093   |
| Cholesterol         | 172.80±22.90       | 162.30±21.10       | 0.139   |
| HDL-C               | 38.60±5.70         | 38.96±5.80         | 0.844   |
| LDL-C               | 101.0±21.40        | 93.56±20.60        | 0.269   |
| Insulin (NPH)       | 35.40±8.40         | 33.80±7.30         | 0.524   |
| Insulin (Regular)   | 20.20±6.30         | 15.80±5.25         | 0.021   |

Table-II: Comparison of mean difference after intervention between two groups.

|                     | Mean difference | P-value |
|---------------------|-----------------|---------|
| **Metformin**       |                 |         |
| BMI                 | 0.41±0.31       | 0.25±0.46 | 0.204   |
| FBS                 | -55.24±14.3     | -10.20±8.43 | <0.001  |
| 2 h pp              | -16.1±4.4       | -25.30±12.46 | 0.003   |
| HbA1C               | -0.34±0.21      | -0.288±0.19 | <0.001  |
| TGs                 | -8.96±6.4       | -17.50±7.90 | <0.001  |
| Cholesterol         | -3.9±1.1        | -10.50±8.70 | 0.002   |
| HDL-C               | -1.14±0.42      | -0.40±1.90  | 0.097   |
| LDL-C               | -1.75±2.43      | -7.44±9.20  | 0.011   |
| Insulin (NPH)       | -1.86±0.74      | -1.56±1.80  | 0.584   |
| Insulin (Regular)   | -0.9±1.4        | -4.30±2.05  | <0.001  |

BMI: body mass index; FBS: fasting blood sugar; 2h pp: 2-hour post-prandial blood sugar; HbA1C: hemoglobin A1C; TG: triglycerides; HDL: high-density lipoprotein cholesterol; LDL: low-density lipoprotein cholesterol; Insulin (NPH): Isophane insulin.
has shown substantial influence on 2 h pp and regular insulin intake decline in treated patients. Variation in HbA1C, Cholesterol, LDL, HDL level, BMI and NPH insulin was not significant in both groups when compared with placebo. Although not statistically significant, there was a trend toward reductions in HbA1C in those treated with both drug (P =0.143).

Our metformin group result was similar to some reported studies. For instance, a meaningful decrease in TG and PPG or a significant reduction in fasting blood glucose level have been reported in metformin group compared with placebo based on different studies. However, there are some controversial aspects about metformin consequences on regular insulin intake, HbA1C or BMI index. Although several investigators believe that there are beneficial effects on HbA1c level, others claim that there is no significant results for those taking metformin and our result analysis put us in the last set.

Alternatively, about acarbose function in diabetic patients, although our results have indicated that the use of medication was associated with significant drop in daily insulin requirements and 2hpp levels, Hollander and colleagues demonstrated that acarbose was associated with significant reductions in HbA1c and there is no significant changes in total daily insulin doses or body weight. Nevertheless, Juntti-Berggren, found that acarbose did produce significantly lower insulin requirements which has the same outcomes as our project. Some of former publications showed just improvement in postprandial glucose levels but no impact on HbA1c or reported that acarbose did decrease HbA1c, FBS and 2-hpp level considerably. It seems that these contradictory outcomes occur because of different approach in each trial.

In future, for better understanding of medication paybacks we have compared the mean difference in BMI and NPH insulin was not significant in both test groups (Table-II). Interestingly, in our data, while metformin has shown more decrease in FBS and Hb A1C level, acarbose has had better effect on improved postprandial glucose level and TG, cholesterol, LDL and regular insulin doses reductions.

Compared with insulin monotherapy, adjunctive therapy with acarbose/metformin has greater antihyperglycemic ability, brings proportionally more T1DM patients to HbA1c goal, and further reduces lipid consumptions. Hence, using insulin sensitive pharmacological drugs may have positive properties on Type-1 diabetes mellitus treatment and improvement of metabolic control.

Declaration of Interest: Nothing.

Compliance with Ethics guidelines: The authors received consent from all patients included in this commentary.

REFERENCES

1. Yki-Järvinen H, Koivisto VA. Natural course of insulin resistance in type I diabetes. New Eng J Med. 1986;315(4):224-230. doi: 10.1056/NEJM198607243150404
2. Model CC. Standards of medical care in diabetes—2015 abridged for primary care providers. Diabetes Care. 2015;38(1):51-594.
3. Nwosu BU, Maranda L, Cullen K, Greenman L, Fleshman J, McShea N, et al. A randomized, double-blind, placebo-controlled trial of adjunctive metformin therapy in overweight/obese youth with type 1 diabetes. PLoS One. 2015;10(9):e0137525. doi: 10.1371/journal.pone.0137525
4. DeGeeter M, Williamson B. Alternative Agents in Type 1 Diabetes in Addition to Insulin Therapy Metformin, Alpha-Glucosidase Inhibitors, Pioglitazone, GLP-1 Agonists, DPP-IV Inhibitors, and SGLT-2 Inhibitors. J Pharm Pract. 2016;29(2):144-159.
5. Bacha F, Klinepeter Bartz S. Insulin resistance, role of metformin and other non-insulin therapies in pediatric type 1 diabetes. Pediatr Diabetes. 2016;17(8):545-558.
6. Orchard TJ, Chang YF, Ferrell RE, Petro N, Ellis DE. Nephropathy in type 1 diabetes: A manifestation of insulin resistance and multiple genetic susceptibilities? Further evidence from the Pittsburgh Epidemiology of Diabetes Complication Study. Kidney Int. 2002;62(3):963-970.
7. Burchardt P, Zwada A, Tabaczewski P, Naskręt D, Kaczmarek J, Marcinkaniec J, et al. Metformin added to intensive insulin therapy reduces plasma levels of glycated but not oxidized low-density lipoprotein in young patients with type 1 diabetes and obesity in comparison with insulin alone: a pilot study. Pol Arch Med Wewn. 2013;123(10):526-532.
8. Chiang J, Peters A, Laffel L. The American Diabetes Association/JDRF Type 1 Diabetes Sourcebook: Am Diabetes Assoc. 2013.
9. Garg V. Noninsulin pharmacological management of type 1 diabetes mellitus. Indian J Endocrinol Metab. 2011;15(Suppl1):55-511.
10. Wood JR, Miller KM, Maahs DM, Beck RW, DiMeglio LA, Libman IM, et al. Most youth with type 1 diabetes in the T1D Exchange Clinic Registry do not meet American Diabetes Association or International Society for Pediatric and Adolescent Diabetes clinical guidelines. Diabetes Care. 2013;36(7):2035-2037.
11. Erciyas F, Taneli F, Arslan B, Uslu Y. Glycemic control, oxidative stress, and lipid profile in children with type 1 diabetes mellitus. Arch Pediatr Adolesc Med. 2004;158(2):134-140.
12. Honardoust M, Reza Saroohkhani M, Arefian E, Soleimani M. Insulin resistance associated genes and miRNAs. Appl Biochem Biotechnol. 2014;174(1):63-80.
13. Honardoust M, Soleimani M, Arefian E, Reza Saroohkhani M. Expression change of miR-214 and miR-135 during muscle differentiation. Cell J (Yakhteh). 2015;17(3):461-470.
14. Vella S, Buetow L, Royle P, Livingstone S, Colhoun H, Petrie J. The use of metformin in type 1 diabetes: a systematic review of efficacy. Diabetologia. 2010;53(5):809-820.
15. Sarnblad S, Kroon M, Aman J. Metformin as additional therapy in adolescents with poorly controlled type 1 diabetes: randomised placebo-controlled trial with aspects on insulin sensitivity. Eur J Endocrinol. 2003;149(4):323-329.

16. Hamilton J, Cummings E, Zdravkovic V, Finegood D, Daneman D. Metformin as an adjunct therapy in adolescents with type 1 diabetes and insulin resistance. Diabetes Care. 2003;26(1):138-143.

17. Lund SS, Tarnow L, Astrup AS, Hovind P, Jacobsen PK, Alibegovic AC, et al. Effect of adjunct metformin treatment in patients with type-1 diabetes and persistent inadequate glycaemic control. A randomized study. PLoS One. 2008;3(10):e3363.

18. Hollander P, Pi-Sunyer X, Coniff RF. Acarbose in the treatment of type I diabetes. Diabetes Care. 1997;20(3):248-253.

19. Juntti-Berggren L, Pigon J, Hellström P, Holst J, Efendic S. Influence of acarbose on post-prandial insulin requirements in patients with Type 1 diabetes. Diabetes, nutrition & metabolism. 2000;13(1):7-12.

20. Nadeau KJ, Chow K, Alam S, Lindquist K, Campbell S, McFann K, et al. Effects of low dose metformin in adolescents with type I diabetes mellitus: a randomized, double-blinded placebo-controlled study. Pediatr Diabetes. 2015;16(3):196-203. doi: 10.1111/pedi.12140

Author’s Contribution:
AZ: Conception & design, acquisition, interpretation of data, final approval of the version to be published.
NE and MH: Acquisition of data, statistical analysis, drafting the article, final approval of the version to be published.
AZ, NE and MH: Accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

DATA SHARING statement by ICMJE

ICMJE statement on data sharing, published June 5, 2017, in the ICMJE journals states that:

“1. As of July 1, 2018 manuscripts submitted to ICMJE journals that report the results of clinical trials must contain a data sharing statement as described below

2. Clinical trials that begin enrolling participants on or after January 1, 2019 must include a data sharing plan in the trial’s registration...If the data sharing plan changes after registration. This should be reflected in the statement submitted and published with the manuscript, and updated in the registry record. Data sharing statements must indicate the following: whether individual de-identified participant data (including data dictionaries) will be shared; what data in particular will be shared; whether additional, related documents will be available (e.g., study protocol, statistical analysis plan, etc.); when the data will become available and for how long; by what access criteria data will be shared (including with whom, for what types of analyses and by what mechanism)... Sharing clinical trial data is one step in the process articulated by the World Health Organization (WHO) and other professional organizations as best practice for clinical trials: universal prospective registration; public disclosure of results from all clinical trials (including through journal publication); and data sharing.”

From: Data Sharing Statements for Clinical Trials: A Requirement of the International Committee of Medical Journal Editors  http://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1002315